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Sammendrag 
Brystkreft er en av de vanligste kreftformene som rammer kvinner, og omtrent 15-30 % av 
brystkrefttilfeller består av en svært aggressiv form kalt HER2-positiv brystkreft. Disse 
pasientene har svulster som overuttrykker human epidermal growth factor receptor 2 (HER2). 
HER2 er et glykoprotein som finnes på celleoverflaten og den ekstracellulære delen (ECD) av 
dette proteinet kan bli proteolytisk kløyvd- og frigjort til blodsirkulasjonen. ECDs evne til bli 
brukt som tumormarkør for oppfølging av pasienter som tidligere har fått diagnosen HER2 
positiv brystkreft, er svært interessant. Det finnes få immunologiske analyser for HER2, og 
målet med denne masteroppgaven var derfor å utvikle en robust og sensitiv immunologisk 
analyse spesifikk for HER2 ECD.  
 
Seks monoklonale antistoffer (M75, M77, M79, M83, M84 and M89) som gjenkjente både 
rekombinant og nativt HER2 ble benyttet i utviklingen av en immunometrisk analyse for 
serum HER2. Antistoffene ble karakterisert, og parkombinasjoner av alle antistoffene ble 
testet for å finne den antistoffkombinasjonen som ga høyest sensitivitet for nativt HER2. Den 
beste parkombinasjonen besto av biotinmerket M89 og europiummerket M83, og den ble 
videre optimalisert og automatisert på et AutoDELFIA instrument. Den nye analysen ble så 
brukt til å teste 15 serumprøver fra pasienter som var vevs-HER2 positive, og prøveverdiene 
ble sammenlignet med prøveverdier fra Siemens ADVIA Centaur Serum HER-2/neu 
immunoassay. Prøveresultatene fra den utviklede analysen ga generelt lavere serum HER2-
verdier sammenlignet med prøveresultatene fra Siemensanalysen, men det var en god lineær 
korrelasjon mellom prøvene. Et sensitivt assay spesifikt for HER2 ECD har blitt utviklet. 
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Abstract 
Breast cancer is one of the most common types of cancer affecting women, and 
approximately 15-30 % of breast cancer patients have a particularly aggressive type called 
HER2 positive breast cancer. These patients have tumors that overexpress human epidermal 
growth factor receptor 2 (HER2). HER2 is a glycoprotein found on the cell surface, and the 
extracellular domain (ECD) of this protein can be proteolytically cleaved and released into the 
blood circulation where it could be useful as a tumor marker to monitor the treatment 
response in HER2 positive patients. However, there are few assays available for HER2. The 
aim of this master thesis was therefore to develop a robust and sensitive immunoassay 
specific for HER2 ECD. 
 
Six monoclonal antibodies (M75, M77, M79, M83, M84 and M89) that recognise both 
recombinant and native HER2 were utilized to develop an immunometric assay for serum 
HER2. The antibodies were characterized, and antibody pair combinations were evaluated in 
a two-site assay to find the antibody combination with the highest sensitivity towards native 
HER2. Biotin labelled M89 and europium labelled M83 was the best combination, and this 
assay was further optimized and automated using an AutoDELFIA instrument. The final 
assay was used to test 15 HER2 positive patient samples and the results were compared with 
patient results obtained in the commercial Siemens ADVIA Centaur Serum HER-2/neu 
immunoassay. The sample results from the new HER2 assay were generally lower than the 
sample results from the Siemens assay, but there was a good linear correlation between the 
assays. Thus, a robust assay with high sensitivity towards HER2 ECD was developed. 
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Abbreviations: 
 
°C  Degrees in Celsius 
Ab  Antibody 
cpm  Counts per minute 
cps  Counts per second 
kDa   kiloDalton 
L  Liter 
M  Molar (mol/L) 
mAb  Monoclonal antibody 
MES  Morpholinoethanesulfonic acid 
mg  Milligram 
ml  Milliliter 
mM  Millimolar 
nm  Nanometer 
PBS  Phosphate-Buffered Saline 
rpm  Rotations per minute 
smAb  Solid phase monoclonal antibody 
µ   Micro 
µg  Microgram 
µl  Microliter 
µm  Micrometer 
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1. Introduction 
1.1. Background and aim of the study 
Breast cancer is the most common type of cancer affecting women, and approximately 10 % 
of women develop this heterogeneous disease throughout their lifetime [1]. Breast cancer can 
be divided into three subgroups; hormone receptor positive, human epidermal growth factor 
receptor 2 positive and triple-negative breast cancer [2]. HER2 positive breast cancer is 
associated with poor prognosis and relapse [3], and approximately 15-30 % of breast 
carcinomas are of this aggressive phenotype [4]. 
 
There are few useful serum tumor markers for breast cancer, and it is a need for new breast 
cancer tumor markers. Several studies using serum HER2 as tumor marker has been 
performed, but the studies show varying results both regarding prognostic value and in 
monitoring the response to treatment [5-7]. The tumor marker laboratory at the Norwegian 
Radium Hospital has long experience in developing immunoassays for tumor markers that are 
as good as, or superior to, existing commercial assays [8;9]. Thus, there was an interest in 
developing a new immunoassay for serum HER2 at the Norwegian Radium Hospital. The aim 
of the study was therefore to develop a robust immunometric assay with high sensitivity and 
specificity for serum HER2.  
 
 
1.2. HER2 
HER2 is a 185 kDa glycoprotein that belongs to the epidermal growth factor receptor (EGFR) 
family, and is encoded by the ERBB2 gene located on chromosome 17q12 [10]. The HER2 
protein consists of an extracellular, a transmembrane and an intracellular domain, where the 
intracellular domain contains tyrosine kinase activity (figure 1.1) [4]. Other members of the 
EGFR family, includes the HER1, HER3 and HER4 proteins. 
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Figure 1.1: An illustration of the HER2 protein, showing the distribution of the extracellular, 
the transmembrane and the intracellular domain. The extracellular part of the HER2 protein 
consists of four domains. Two of these domains (I and III) are associated with ligand binding, 
while the two remaining domains (II and IV) are involved in dimerization of receptors on the 
cell surface [11]. The monoclonal antibodies pertuzumab and trastuzumab, used for the 
treatment of HER2 positive breast cancer patients, targets the II and IV extracellular domains 
of the HER2 protein, respectively [11]. Figure copied from [11]. 
 
The tyrosine kinase activity of the HER proteins is activated by binding of a ligand to the 
extracellular domain, which trigger dimerization of HER proteins on the cell surface [12]. The 
dimer formed may either be a homodimer, a formation between two similar HER proteins, or 
a heterodimer, a formation between two different HER proteins [12]. Activation of the 
tyrosine kinase in the intracellular domain of HER2 induces a cascade of reactions providing 
intracellular signals to the cell nucleus [12]. 
 
In normal cells, the gene expression is strictly regulated. Mutations in the genes encoding the 
HER receptors may affect this regulation and allow for increased gene amplification. The 
HER proteins contribute to the regulation of cell growth and survival [13]. If the gene 
encoding HER2 proteins are subjected to mutations, it may result in increased amplification 
of the HER2 gene. This will further result in an increased production of HER2 receptors, and 
when activated, intracellular signals mediated by the receptors to the nucleus may result in 
uncontrolled and rapid cell growth [14]. 
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Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are two common 
methods for differential diagnosis of breast cancer, and these techniques are used, among 
others, to evaluate the HER2 status and thus distinguish between HER2-positive and HER2-
negative tissue [15]. The techniques may in this way give an indication of the type of therapy 
the patient will benefit from.  
 
Following surgical removal of tumor tissue, HER2 positive breast cancer patients are treated 
with conventional chemotherapy and radiotherapy in combination with immunotherapy. In 
any targeted therapy, the antigen of interest must be significantly higher expressed in tumor 
cells relative to normal cells. Normally, epithelial cells of breast tissue express low levels of 
HER2 in healthy humans. In tumor cells that over-express HER2, about 500 000 – 2 000 0000 
HER2 receptors are found on the cell surface, while between 25 000 and 185 000 receptors 
are found on non-over-expressing tumor cells [11]. Trastuzumab (Herceptin) is a humanized 
recombinant anti-HER2 monoclonal antibody utilized for treating HER2 positive breast 
cancer by targeting the extracellular domain IV of HER2 [12]. By targeting HER2, 
trastuzumab may inhibit dimerization of the receptors and thereby inhibit the signal for tumor 
growth [11]. Pertuzumab is another anti-HER2 monoclonal antibody that can be used in 
combination with Trastuzumab. 
 
 
1.3.  Tumor markers 
Tumor markers are compounds, usually proteins, produced by tumor tissue and released into 
the blood circulation [16]. These proteins are usually observed at low concentration levels in 
the blood of healthy people, but in the presence of a tumor, the concentration levels of the 
markers associated with that particular tumor may be elevated. Immunoassays for tumor 
markers are normally not sensitive and specific enough to be utilized as diagnostic tests alone. 
Their main uses are for monitoring the response to treatment and detection of relapse of 
disease. 
 
The extracellular domain (ECD) of the HER2 protein is proteolytically cleaved by 
metalloproteases and released into the blood circulation [15]. Using serum measurements of 
HER2 ECD in blood samples from HER2 positive patients to monitor the tumor response to 
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therapy is of great interest. Serum testing would be of even greater interest if the HER2 ECD 
could be used as a marker for recurrence of HER2-positive cancer. 
 
 
1.4.  Monoclonal antibodies 
B-lymphocytes play an important role in adaptive immunity by recognizing foreign antigens 
and secreting specific antibodies. B-lymphocytes are stimulated by the binding of antigens to 
their antibody receptors on the cell surface, which may lead to the development of specialized 
plasma cells. These cells protect the host organism from foreign pathogens, by secreting 
antibodies specific to antigens on the invading pathogen [17].  
 
An antigen can be almost any type of biological molecule that can be recognised by 
antibodies [17]. An epitope is a specific site on the antigen where antibodies can bind. One B-
cell produces monoclonal antibodies that bind to one specific epitope on the antigen. During 
the lifetime of a human being, about 1010 different antibodies are synthesized in the body 
[18]. While monoclonal antibodies are homogeneous, polyclonal antibodies are collections of 
many monoclonal antibodies and do not recognize one specific epitope, but may detect 
several epitopes on the antigen of interest.  
 
Immunoglobulin G (IgG) is a 150 kDa glycoprotein and is the most common class of 
antibodies used in immunoassays. The IgG molecule consists of two identical heavy - and two 
identical light polypeptide chains, which are bound by disulphide bonds, see figure 1.2. The 
heavy chains contain four domains, while the light chains contain two domains. The 
polypeptide chains are composed of two types of domains, constant -and variable domains. 
Hypervariable regions are found in the variable domains of both the light and the heavy 
chains and is where the antibody binds the antigen.  
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Figure 1.2: A simplified figure of the structure of an IgG molecule, showing the distribution 
of the light-and heavy polypeptide chains and the constant- and variable domains. At the VH 
(variable heavy chain) and VL (variable light chain) domains in the Fab part of the IgG 
molecule is the antigen-binding site. Figure copied from Lea T. [17]. 
 
The antigen binding sites on the IgG molecule is significantly smaller than the ECD of the 
HER2 protein. The HER2 ECD contains multiple epitopes which may be either overlapping 
or non-overlapping, and several IgG molecules can bind to epitopes on a single HER2 ECD. 
Overlapping epitopes may lead to competition between the antibodies that try to bind, while 
non-overlapping epitopes may allow antibodies with different specificity towards the epitopes 
to bind independently of each other.  
 
 
1.5.  Immunological analysis  
Immunoassay is a technique used to detect and quantify the amount of a certain antigen, based 
on the specificity of the reaction between an antibody and its antigen. The use of antibodies in 
immunological analysis has great benefits due to the vast variation, specificity and high 
affinity of the antigen-antibody reaction [19].  
 
Immunoassays can be divided into competitive and non-competitive (immunometric) assays. 
Competitive assays usually utilize polyclonal antibodies and use antibodies in deficit, while 
immunometric assays normally use monoclonal antibodies (mAbs) in excess, and does often 
have the benefit of being more sensitive than competitive assays [17].  
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One type of immunometric method referred to as a sandwich assay, utilizes antibodies that 
bind to different epitopes on the antigen, hence, antibodies with different specificities. A 
monoclonal antibody is immobilized to a solid phase (e.g. a bead or the wall of a well), which 
is incubated with the sample containing the specific analyte, see figure 1.3. Addition of a 
second antibody labelled with a reporter molecule will then bind to the immobilized antigen 
and make it possible to measure the amount of antigen present.  
 
 
Figure 1.3: A simplified illustration of a two-site assay. 1. Antibodies (black) are immobilized 
on the walls of a microtitre well. 2. Then the antigen of interest is added to the well and is 
bound to the antibody. 3. Europium labelled antibodies (light green) are added as tracer.  
 
Interference by heterophilic antibodies can be a problem in immunoassays [20]. Heterophilic 
antibodies are found in the blood of some patients, and it is crucial that the assays are 
protected against these antibodies to avoid false high values and possible misdiagnosis. To 
prevent this problem, several proteases such as papain, pepsin or bromelain can be utilized to 
specifically fragment IgG into biologically active fragments. Papain fragments IgG into Fab- 
and Fc fragments (figure 1.4), and the proteases bromelain and pepsin cut the IgG molecule 
into F(ab´)2 and Fc fragments, where the F(ab´)2 fragments contain two antigen specific 
binding sites, called paratopes [19]. Bromelain has been found to cleave mouse IgG1 better 
than papain [21]. When F(ab´)2 or Fab fragments are used in an immunoassay, the 
interference due to heterophilic antibodies that bind to the Fc part of the IgG molecule is 
eliminated [22]. The majority of heterophilic antibodies bind to the Fc part of the antibody, 
but some are able to bind to the F(ab´)2 fragments [22]. An additional way to prevent 
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interference in these assays is to add a blocking antibody or blocking reagent to the 
reagents/buffers used in the assay [23]. Aggregated antibodies used as blocking antibodies in 
the assay are more potent to block heterophilic antibodies than antibodies that are not 
aggregated, and it is important that the blocking antibody is from the same species and of the 
same isotype as the reagent antibodies [23]. 
 
 
Figure 1.4: A simplified figure of how pepsin and papain fragment IgG molecules, and the 
distribution of the resulting fragments. Bromelain reacts similar to pepsin. Figure copied from 
Lea T. [17]. 
 
The monoclonal antibodies utilized in this thesis were produced before the thesis began, by 
the department of medical biochemistry at the Norwegian Radium Hospital. The mAbs were 
produced after immunization of BALB/c mice with recombinant HER2. Initial tests identified 
monoclonal antibodies produced by 19 cell lines, where the antibodies recognized both 
recombinant and native HER2. The six most promising candidates (M75, M77, M79, M83, 
M84 and M89) were subcloned and further tested.  
 
In this master thesis, the six monoclonal antibodies specific for HER2 ECD were 
characterized and evaluated in two-site assays utilizing different combinations of the 
antibodies to identify the best assay combination that recognized native HER2. Monoclonal 
antibodies labelled with biotin were used as solid phase antibodies on streptavidin-coated 
plates in order to exploit the strong affinity between streptavidin and biotin, with a 
dissociation constant, KD = 4 x 10-14 M [24]. The second (tracer) antibody was labelled with 
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europium (III) chelates as reporter molecules. The final assay was optimized and automated 
using an AutoDELFIA instrument. 
 
There are several methods that can be used to label antibodies. One method is radioisotopic 
labelling, were iodine-125 (125I) is the most common radioisotope utilized in immunoassays 
[19]. It emits gamma rays that are detected by solid scintillation counting that measure 
ionizing radiation [19]. Time-resolved fluorescence is another method where Europium 
(Eu3+)-chelate is commonly used as tracer molecule. This method is based on counting the 
fluorescence emission after a certain time delay, to ensure that it is the signal from the 
specific substance that is counted [25]. Eu3+-chelate has a long fluorescence decay time that 
makes it easier to distinguish the fluorescence emission from that specific substance than 
from background interference [26]. 
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2. Materials and methods 
More detailed information about the chemicals and proteins are found in appendix 1.  
 
 
2.1.  Determination of protein concentrations 
In a protein or a peptide, it is primarily the aromatic amino acids tryptophan and tyrosine that 
are able to absorb light at 280 nm. The absorbed light was measured at 280 nm using a 
spectrophotometer. The extinction coefficient for a whole mouse IgG is 1,43. This number 
was used after measuring the absorbance at 280 nm to calculate the antibody concentration in 
mg/ml by dividing the absorbance at 280 nm value with the extinction coefficient.  
 
 
2.2.  Purification of antibodies on protein A column 
Materials: 
• Supernatant containing the protein 
• Binding buffer (1x: 0,1 M Na2HPO4 and 0,01 % NaN3 (pH 8,2)) 
• 0,25 M EDTA (pH 8,2)  
• Protein A elution buffer (1x: 25 mM citric acid, 25 mM Na2HPO4, 25 mM NaCl, 0,01 
% NaN3 (pH 3,1)) 
• 1 M NaOH  
• rProtein A Sepharose (Fast Flow, Pharmacia, GE Healthcare Life Sciences) 
• Whatman sterile filter, 0,22 µm (GE Healthcare Life Sciences) 
• Beckman Coulter Avanti J-25I Centrifuge (Nerliens Meszansky AS) 
• PHM 92 LAB pH METER (Radiometer Copenhagen) 
• UV-1800 Spectrophotometer (Shimadzu) 
• Econo Pump, system controller and fraction collector (Bio Rad) 
• 20 % ethanol  
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Preparation of sample: 
The sample was spun for 30 minutes at 10 000 rpm at 4 °C. Added 0,25 M EDTA to final ≈ 
7,7 mM and binding buffer 5x to final 1x. pH was adjusted to 8,2 using 1 M NaOH, and the 
sample was filtered with 0,22 µm filter to remove any protein precipitates. 
 
Procedure preformed at 4 °C: 
The column was first equilibrated with 5-10 times the column volumes of binding buffer, and 
pH and absorbance at 280 nm (A280) was measured. Then the sample was added, and the 
column was washed with 5-10 column volumes of binding buffer or until the A280 of the flow 
through had reached the baseline. The antibody was then eluted by adding 3-4 column 
volumes of Protein A elution buffer. pH and A280 were measured in the fractions during the 
whole elution to find out when the protein was eluted. The column was then re-equilibrated 
with binding buffer until A280 reached 0. The fractions with high absorbance were collected 
and pooled. pH was adjusted to 7 with 1 M NaOH and A280 was measured, and the sample 
was then filtered through a 0,22 µm filter. Finally, the antibody concentration was calculated 
by dividing the A280 value by the extinction coefficient for immunoglobulin G. 
 
Wash and storing of the column: 
The column was washed with five column volumes of ultra-pure water. The column was then 
washed with 5 column volumes of 20 % ethanol and stored in the ethanol solution at 4 ºC. 
 
The purification was performed as described earlier [21]. 
 
 
2.3. Isotyping of antibodies 
Materials: 
• Antibodies 
• PBS (0,01 M NaH2PO4, 0,15 M NaCl (pH 7,2)) 
• Vortex-Genie 2 (Scientific industries) 
• IsoStrip Mouse Monoclonal Antibody Isotyping Kit including capped development 
tubes containing lyophilized latex beds and isotyping strips (Roche) 
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Procedure: 
The antibodies were diluted to 0,5 µg/ml in PBS. 150 µl of each diluted antibody sample was 
dispensed into different capped development tubes containing lyophilized latex beads and 
incubated for 30 seconds at room temperature. The solutions were then mixed with a vortex 
mixer until all the beads were dissolved. One isotyping strip were placed in each development 
tube and incubated for 5 – 10 minutes. Then a positive control band appeared, and the results 
could be read. 
 
 
2.4.  Fragmentation of IgG to F(ab´)2 
Materials: 
• Antibodies 
• Bromelain 
• Protease inhibitor E-64 
• Buffer with pH 7 (1x: 0,05 M Tris, 0,1 M NaCl and 5 mM EDTA) 
• Binding buffer (5x) 
• rProtein A Sepharose  
• Whatman sterile filter, 0,22 µm 
• PHM 92 LAB pH METER  
• UV-1800 UV Spectrophotometer  
• Water bath (Grant) 
 
Procedure:  
pH of the antibody sample was adjusted to 7,5 with binding buffer, to obtain an optimal 
fragmentation. The protein A column was equilibrated with binding buffer until pH 8,2 was 
reached. The antibody sample was filtered with 0,22 µm filter to remove any aggregates. A280 
was measured and the antibody concentration was calculated using the extinction coefficient. 
The sample was added 1:10 volume ratio of buffer with pH 7, and bromelain was added to get 
a 1:20 ratio between the antibody and bromelain. The solution was incubated in a water bath 
at 37 °C for 2 hours, and the fragmentation reaction was stopped by adding 10 µg/ml of the 
protease inhibitor E-64. Finally, the F(ab´)2 and Fc fragments were separated using a protein 
A column. This procedure is described in “2.2 Purification of antibodies on protein A 
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column”. Calculations are shown in appendix 2. The fragmentation was performed as 
described earlier [21]. 
 
 
2.5.  SDS-polyacrylamide gel electrophoresis 
SDS-polyacrylamide gel electrophoresis is a method utilized to separate proteins based on 
their size. Using the anionic detergent SDS, a reducing agent and heat, the proteins become 
denatured and the negatively charged SDS give the proteins a negative charge. The proteins 
will then migrate to the positive pole of an electric field based on the protein size.  
 
Materials: 
• Antibodies 
• NuPAGE 4-12 % Bis-Tris Protein Gel (Novex, Life Technologies) 
• Mes-SDS Running buffer NuPAGE 20x (1x: 50 mM MES, 50 mM Tris Base, 0,1 % 
SDS, 1 mM EDTA (pH 7,3)) (Novex, Life Technologies) 
• Sodium dodecyl sulphate loading buffer (SDS Lb)  (1x: 50 mM Tris, 2 % SDS, 0,1 % 
bromophenol blue, 10 % glycerol) 
• Imperial Protein Stain  (Thermo Scientific) 
• SeeBlue Plus2 Prestained Standard (Novex, Life Technologies) 
• Water bath 
 
Sample treatment:  
The sample was boiled in a water bath for 3 minutes to denature the proteins.  
 
Procedure: 
The Mes-SDS Running buffer NuPAGE 20 was diluted to 1x with deionized water. The 
NuPAGE 4 – 12 % Bis-Tris Protein Gel was placed in the electrophoresis chamber, and the 
chamber was filled with the diluted Mes-SDS Running buffer. Then the samples could be 
loaded. 10 µl SeeBlue standard was added to the first well. 15 µl sample containing the F(ab)2 
–fragment and 5 µl SDS Lb four times concentrated was mixed and 10 µl of the mix was 
added to the second well. 5 µl of the sample containing the Fc - part and possibly some 
remaining non-fragmented antibodies was mixed with 5 µl SDS Lb 2 times concentrated and 
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added to the third well. 5 µl of a sample containing a whole IgG antibody and 5 µl SDS Lb 2 
times concentrated was mixed and added to the fourth well. The proteins and fragments in the 
gel were separated at 200 V.  
 
Procedure for staining the gel: 
Ultra-pure water was used to wash the gel for 5 minutes and the wash was repeated three 
times. Then, the gel was stained with imperial protein staining on a shaker for fifteen minutes. 
Finally, the gel was washed with ultra-pure water for one hour on a shaker. 
 
 
2.6.  Biotin labelling of antibodies and F(ab´)2 fragments 
Materials: 
• Antibodies 
• EZ-link Sulfo –NHS-LC Biotin  
• PD 10 Desalting Columns (GE Healthcare Life Sciences) 
• Pyro-mag stir (Cenco Instrumenten B. V.) and a magnet 
• 1 M glycine 
• Whatman sterile filter, 0,22 µm 
• UV-1800 Spectrophotometer  
• PHM 92 LAB pH METER 
• Elution buffer (0,05 M Tris, 0,15 M NaCl, 0,05 % NaN3 (pH 7,8)) 
 
Procedure: 
The antibodies must be in a buffer absent of amino groups. To determine the protein 
concentration, A280 was measured and the protein concentration was calculated. The pH was 
adjusted to 7,5 and 10 mM NHS-biotin (5x molar excess of biotin; 3,33 µl/mg monoclonal 
antibody) was added while the sample was stirred. The solution was then incubated at room 
temperature for 30 minutes, and 1 M glycine (100 µl/ml solution) was added to stop the 
reaction. PD-10 columns with elution buffer were used to remove the free biotin in each 
sample. The sample was then filtered with 0,22 µm filter. A280 was measured and the protein 
concentration was calculated. The biotin labelling was performed as described earlier [21]. 
 
	  	  	  	  
	   Materials	  and	  methods	   	  	   	  
14	  
2.7.  Iodine labelling of antibodies 
I only observed during this procedure. The procedure was performed in a separate room with 
lead cover and equipment used only during experiments with radioactivity. 
 
Materials:  
• Antibodies 
• NAP-5 columns (GE Healthcare Life Sciences) 
• Iodine-125 
• IODO-GEN Pre-Coated Iodination Tubes (Pierce, Thermo Scientific) 
• Iodination buffer (0,025 M Tris and 0,4 M NaCl (pH 7,4)) 
• Iodination elution buffer (0,01 M NaPO4, 0,3 M NaCl, 0,01 % Thimerosal and 0,1 % 
BSA (pH 7,3)) 
• Saturated tyrosine solution 
• Ethylene glycol 
• Soft Nitrile Examination Gloves (Klinion Protection) 
• Wallac WIZARD 1470 Automatic Gamma Counter (Wallac, Perkin Elmer life 
sciences) 
• Extra lab coat 
 
Procedure: 
A NAP-5 column was equilibrated with 10 ml iodination elution buffer and the iodogen tube 
was prewashed with 1 ml iodination buffer. 100 µl iodination buffer with 2,5 µl 125I (0,125 
nmol) was added. The tube was incubated for 5 minutes at room temperature while shaking 
the tube a few times a minute. The 125I-solution was added to a tube containing 100 µl of 
protein solution in iodination buffer. The tube was incubated at room temperature for 5 
minutes. 50 µl tyrosine solution (10 mg/ml) was then added to the tube and the tube was 
incubated for 5 minutes in room temperature. To separate the free iodine in the solution from 
iodine bound to the protein, the solution was separated on a NAP-5 column. The protein was 
eluted in 0,2 ml fractions of iodination elution buffer, and radioactivity were measured using 
Wallac WIZARD 1470 Automatic Gamma Counter. The appropriate fractions were mixed 
and 1:2 ratio of ethylene glycol was added, and the radioactivity in 10 ml of the solution was 
measured. 
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2.8.  Europium labelling of antibodies 
Materials: 
• Antibodies 
• Europium p-isothiocyanatophenyl-EDTA complex 
• Molecularporous membrane tubing (MWCO: 12-14000) (Spectral Medical Industries, 
Inc.) 
• Whatman sterile filter, 0,22 µm 
• Borate buffer (0,02 M borate, 0,15 NaCl, pH 8.0) 
• PD 10 Desalting Columns  
• Amicon ultra, 50 K (Millipore) 
• Elution buffer  
• DELFIA®/AutoDELFIA® Enhancement solution (Wallac, Perkin Elmer life sciences) 
• UV-1800 UV Spectrophotometer 
• Distillate water  
• VictorTM 1420 Multilabel Counter (Wallac, Perkin Elmer life sciences) 
 
Eu-isothiocyanat pre-treatment: 
0,2 mg europium3+-chelate was dissolved in 0,1 ml water. 
 
Antibody pre-treatment: 
The antibody samples were dialysed or added to a PD-10 column to change the buffer to 
borate buffer. The antibody solution was concentrated to 1-2 mg/ml on an Amicon ultra, 50 
K. The samples were then filtered with 0,22 µm filters. 
 
Procedure: 
Antibody and europium3+-chelate were mixed with 12X molar excess of europium3+-chelate. 
1/10 volume of 0,1 M borate buffer was added to the reaction mix, and the solutions were 
incubated for 72 hours at room temperature. Gel filtration by PD-10 columns was utilized to 
separate free- and bound Eu3+-chelate in the solutions. The columns were first equilibrated 
with 25 ml of elution buffer, and then the samples were added to the columns and eluted with 
elution buffer in 0,5 ml fractions. 5 µl of each fraction was first diluted 1:100 in 0,5 ml elution 
buffer. 5 µl of the diluted solution was further diluted 1:40 in 0,2 ml enhancement solution 
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and fluorescence was measured. The peak fractions were collected, and fluorescence was 
measured in dilutions of 1:10 000 and 1:100 000 against a 1:100 diluted europium standard 
(100 nmol/L) in enhancement solution, to calculate the concentrations of the incorporated 
europium molecules. A280 was measured in the collected samples and the protein 
concentration was calculated. The calculations for the number of Eu3+ per IgG and recovery 
(%) are shown in appendix 3. The europium labelling was performed as described earlier [21].  
 
 
2.9.  Coating of plates with different antibodies 
Materials: 
• Antibodies 
• Blocking buffer (1x: 0,05 M Tris, 6 % D-sorbitol, 0,1 % BSA, 0,05 % NaN3 and 0,2 
mM DTPA (pH 7,0)) 
• Coating buffer (1x: 27,6 g 0,2 M NaH2PO4 in 1 L distilled water) 
• AutoDELFIA wash buffer (0,05 M Tris, 0,15 M NaCl, 0,1 % Germall and 0,05 % 
Tween 20) (Wallac, Perkin Elmer life sciences) 
• DELFIA Platewash (Wallac, Perkin Elmer life sciences) 
• Pyro-mag stir and a magnet 
• C8 maxi break apart nunc-immuno module (Nunc A/S)  
• Soft absorbent paper 
 
Procedure: 
Day 1: Each well should contain 1 µg antibody with a total volume of 200 µl per well.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
The antibodies were diluted to 5 µg/ml in coating buffer, mixed and 200 µl of the dilution was 
added to each well. The plates were put in a moist box at 37 °C and incubated over night. 
Day 2: The plates were washed two times with AutoDELFIA wash buffer on DELFIA plate 
washer and 300 µl blocking buffer was added to each well. The plates were incubated at room 
temperature over night in a moist box.  
Day 3: The blocking buffer was removed using the DELFIA platewash and the remaining 
liquid in the wells were “hit” out on soft absorbent paper. The plates were dried at room 
temperature for 3 hours and were then ready for use. 
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Calculations are shown in appendix 4. The coating of plates were performed as described 
earlier [27]. 
 
 
2.10. Cross-inhibition 
Materials: 
• Recombinant human HER2 labelled with iodine-125 
• MAbs: M75, M77, M79, M83, M84 and M89 
• PBS with 0,3 % BSA 
• C8 maxi break apart nunc-immuno module coated with mAbs (1 µg/well) 
• DELFIA Platewash 
• DELFIA Plateshake (Wallac, Perkin Elmer life sciences) 
• AutoDELFIA wash buffer 
• Wallac WIZARD 1470 Automatic Gamma Counter 
 
Procedure: 
50 µl iodine labelled recombinant HER2, 0,07 µg/ml, was mixed with 50 µl mAb 10 µg/ml in 
PBS with 0,3 % BSA for each of the six antibodies. As a negative control, 50 µl iodine 
labelled recombinant HER2 mixed with 50 µl PBS with 0,3 % BSA was used. The reaction 
solutions were incubated for 1 hour at room temperature. Calculations are shown in appendix 
5. 100 µl of the samples were added to mAb-coated plates in such a way that all antibody 
combinations were tested. The plates were incubated for 1 hour at room temperature on 
DELFIA plateshaker, and were then washed three times with AutoDELFIA wash buffer using 
the DELFIA platewash. Finally, radioactivity was counted in each well and percent binding 
calculated using the Wallac WIZARD 1470 Automatic Gamma Counter. The cross-inhibition 
test was performed as described earlier [28]. 
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2.11. Testing antibody combinations 
Materials: 
• C8 maxi break apart nunc-immuno module plates coated with mAbs: M75, M77, M79, 
M83, M84 and M89 
• M75, M77, M79, M83, M84 and M89 labelled with iodine-125 
• PBS with 0,3 % BSA 
• 100 µg/L HER2 
• DELFIA Platewash  
• DELFIA Plateshake 
• Wallac WIZARD 1470 Automatic Gamma Counter 
• AutoDELFIA wash buffer 
 
Procedure: 
100 µl of 100 µg/L recombinant human HER2 was added to the mAb plates. 100 µl PBS with 
0,3 % BSA was used as negative control. The plates were incubated for 1 hour at room 
temperature on a DELFIA plateshaker, and were then washed three times with AutoDELFIA 
wash buffer using the DELFIA platewasher. 100 µl of ≈ 50 000 cpm iodine labelled mAbs 
were added to the wells in such a way that all antibody combinations were tested. The plates 
were incubated for 1 hour at room temperature on a DELFIA plateshaker, and were then 
washed six times with AutoDELFIA wash buffer. Finally, radioactivity was counted in each 
well and percent binding was calculated. 
 
 
2.12. Preparation of standards A, B, C, D, E and F 
The standards consisted of different concentrations of recombinant human ErB2/HER2 and 
standard matrix (50 mM Tris, 150 mM NaCl, 0,1 % Germall and 6 % BSA). 
 
First 1 ml of HER2 was diluted 1:100 in 99 ml of standard matrix. 
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Then the standards were prepared as follows:  
Standard F: 12 ml 1:100 dilution of HER2 and 48 ml standard matrix (1:5) 
Standard E: 15 ml standard F and 45 ml standard matrix (1:4) 
Standard D: 15 ml standard E and 45 ml standard matrix (1:4) 
Standard C: 15 ml standard D and 45 ml standard matrix (1:4) 
Standard B: 15 ml standard C and 45 ml standard matrix (1:4) 
Standard A: Standard matrix 
 
Then the calibrators were aliquoted and stored at – 30 °C. Finally they were calibrated against 
the Siemens Healthcare Diagnostics ADVIA Centaur Serum HER-2/neu immunoassay and 
the concentrations of standard A-F ranged from 0 to 350 µg/L. 
 
 
2.13. Optimization of the immunoassay 
The optimization of the assay included testing of different incubation times for the second and 
third incubation period, and testing several concentrations for the biotin labelled antibody and 
the europium labelled antibody. 
 
Standard A-F and a control reference material, breast cancer cell line SK-BR3, was used in 
the optimization. This reference material has an overexpression of the HER2 gene product, 
namely the HER2 protein. Pooled patient sera from patients at the Norwegian Radium 
Hospital were also used as control samples. These two in-house control samples, DNR control 
1 and DNR control 2, had concentration 18,7 µg/l and 165 µg/l respectively. Two control 
samples from Siemens were also included in the tests, Siemens control 1 and Siemens control 
2, which contain 12.8 µg/l and 98.2 µg/l of recombinant HER2 respectively.  
 
Materials:  
• M89- and M89 F(ab´)2 fragment labelled with biotin 
• M83 labelled with europium 
• AutoDELFIA buffer (0,05 M Tris, 0,15 M NaCl, 0,02 mM DTPA, 0,1 % Germall, 
0,01 % Tween 20, 5 % BSA, 0,5 % bovine IgG, 15 mg/L MAK 33 and 3 mg/L 
tartrazine) 
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• AutoDELFIA wash buffer 
• AutoDELFIA Streptavidin Microtitration Strips, 8 x 12 wells (Wallac, Perkin Elmer 
life sciences) 
• DELFIA Plateshake 
• DELFIA Platewash  
• Standard A-F 
• Control samples 
• Cell line SK-BR3 (American Type Culture Collection ATCC) 
• AutoDELFIA Enhancement solution  
• Disposable plastic pipette (Nunc Brand Products) 
• VictorTM 1420 Multilabel Counter 
• AutoDELFIATM 1235 Automatic immunoassay system (Wallac, Perkin Elmer life 
sciences) 
 
The first step in the optimization was to determine the optimal incubation times. Started by 
testing different incubation times for the second incubation period, after the samples were 
added. All of the optimization tests were performed manually. However, due to poor parallel 
values for some of the standard curves, parts of the optimization testing were performed again 
using the AutoDELFIA instrument.  
 
Procedure: 
200 µl of 2 µg/ml biotin labelled M89 in AutoDELFIA buffer was added to each well in a 
streptavidin plate, and incubated for 30 minutes at room temperature on the DELFIA 
plateshaker. The wells were washed 3 times with AutoDELFIA wash buffer on the DELFIA 
platewasher. 150 µl AutoDELFIA buffer and 50 µl of the standards and samples were added 
to the wells, and the plates were incubated at room temperature for either 30, 60, 90 and 120 
minutes on the DELFIA plateshaker and washed 6 times with AutoDELFIA wash buffer. 200 
µl of 1 µg/ml europium labelled M83 in AutoDELFIA buffer was added to the wells. The 
plates were incubated for 60 minutes at room temperature on the DELFIA plateshaker and 
then washed 6 times. Finally, 200 µl enhancement solution was added and the plates were 
incubated for 5 minutes at room temperature on the DELFIA plateshaker. Europium cps was 
then measured on VictorTM 1420 Multilabel Counter. 
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The procedure for testing incubation times for the third incubation period, after adding 
europium labelled M83 antibody, was identical, except for the second incubation period. The 
second incubation period was 60 minutes, and the incubation times tested for the third 
incubation period were 30, 60, 90 and 120 minutes.  
 
After testing incubation times, different concentrations of M89 labelled with biotin and M83 
labelled with europium were tested. Instead of using the whole antibody, F(ab´)2 fragment of 
M89 was utilized. This procedure was identical with the procedure for testing the incubation 
times, except that the third incubation period was 60 minutes. First, biotin labelled M89 
F(ab´)2 fragment with 1, 2, 3 and 4 µg/ml concentration in AutoDELFIA buffer was tested. 
Then europium labelled M83 with 0,5 µg/ml, 1,0 µg/ml and 2,0 µg/ml concentration in 
AutoDELFIA buffer was tested. 
 
The assay was ultimately used to test serum samples from HER2 positive breast cancer 
patients using the AutoDELFIA instrument and compared with a commercially available 
immunoassay for HER-2/neu (ADVIA Centaur, Siemens, Norway). All participants had given 
written informed consent to participate in the study. 
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3. Results 
3.1.  Purification and characterization of the monoclonal 
antibodies 
The monoclonal antibodies were produced at the Department of Medical Biochemistry at the 
Norwegian Radium Hospital prior to the start of this project. The monoclonal antibodies were 
produced in cell cultures.  
 
All of the antibodies were purified on protein A columns. Characterization of the antibodies 
was done with two independent methods. Cross-inhibition is a method to characterize the 
antibodies towards each other and was performed to identify whether the antibodies had 
overlapping or non-overlapping epitopes. Isotyping is a method to determine the specific 
isotype of an antibody. 
 
 
3.1.1. Cross-inhibition 
Cross-inhibition was performed to separate the six different antibodies towards HER2 into 
groups related to the epitope specificities. Based on the similarity and differences in the 
inhibition patterns, it was possible to separate the antibodies into different groups. The 
differentiation was based on complete inhibition (> 80 %) and the inhibition pattern towards 
the other antibodies. The six antibodies were divided into three groups; A, B and C. Group A 
was further divided into the two subgroups A1 and A2. Group A1 consisted of M75 and M89, 
group A2 consisted of M77, group B included M79 and M83, while group C only comprised 
M84 (table 3.1). Complete inhibition (> 80 %) is marked as bold type in the table below. The 
cross-inhibition results from all the antibody combinations with two identical mAbs show 
almost 100 % inhibition. 
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Table 3.1: The results of the cross-inhibition test as the percent inhibition (100 % - % 
binding) between the HER2 antibodies. 
 
smAb 
 
Groups 
Inhibiting monoclonal antibody 
M75 M89 M77 M79 M83 M84 
A1 A2 B C 
M75 A1 91 95 17 55 56 -2 
M89 83 100 92 -1 3 5 
M77 A2 82 96 97 -42 4 -4 
M79 B 36 65 -5 99 98 -1 
M83 48 72 -1 99 100 6 
M84 C -66 -9 -28 -3 30 98 
 
 
3.1.2. Isotyping of antibodies 
The isotyping method provides information about what isotype the antibody consist of and the 
type of light chain. Table 3.2 shows that all of the six mAbs have kappa light chains. M83 has 
IgG2a isotype, while the remaining mAbs have IgG1 as their isotype.  
 
Table 3.2: An overview of the results from the isotyping test of M75, M77, M79, M83, M84 
and M89. 
mAb M75 M77 M79 M83 M84 M89 
Isotype IgG1 IgG1 IgG1 IgG2a IgG1 IgG1 
Type of 
light chain 
κ 
 
κ 
 
κ 
 
κ 
 
κ κ 
 
 
 
3.2. Antibody combinations 
To identify the best antibody combinations, M75, M77, M79, M83, M84 and M89 antibodies 
were tested against each other using mAb coated plates and 125I-labelled mAbs as tracer 
antibodies. The values from the negative control were subtracted from the resulting values 
and the results are shown in figure 3.2. The three best antibody combinations all had M89 as 
solid phase, with M79, M83 and M84 as tracer mAbs. A table with the exact values are shown 
in Appendix 6. 
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Antibody combinations with recombinant HER2
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Figure 3.2: The coloured bars show the binding of the different mAbs labelled with 125I in a 
sandwich assay with recombinant HER2 immobilized to plates coated with the different 
mAbs. Red = 125I -M75, orange = 125I -M77, yellow = 125I -M79, green = 125I -M83, turquoise 
= 125I -M84 and blue = 125I -M89. 
 
 
3.3. Fragmentation of solid phase antibody 
The solid phase antibody was fragmented into F(ab’)2 and Fc fragments using bromelain, 
followed by separation of the fragments on protein A column. SDS-polyacrylamide gel 
electrophoresis was performed to evaluate the fragmentation. Figure 3.1 is a picture of the gel 
after fragmentation and separation of the M89 antibody, where well number 2 contain the 
F(ab’)2 fragment. Well number 3 contains the Fc part and some remaining unfragmented M89 
indicating that the fragmentation was not complete. However, the F(ab’)2 fragment used 
further in the studies was pure.  
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Figure 3.1: Picture of a SDS-polyacrylamide gel. Well 1: SeeBlue Plus2 Prestained Standard. 
Well 2: F(ab’)2 fragment of the M89 antibody. Well 3: Unfragmented M89 antibody and the 
Fc fragment of M89. Well 4: The whole antibody. 
 
 
3.4. Europium labelling of the antibodies 
The antibodies were labelled with europium as tracer molecule, and the table below shows the 
number of europium molecules per antibody and percent recovery. Calculations are shown in 
appendix 3. The incorporation of Eu3+ per monoclonal antibody molecule varied from 5,9 to 
8,2. 
 
Table 3.3: An overview of the number of labelled europium molecules per antibody and the 
percent recovery.  
mAb M79 M83 M84 M89 
Number of Eu3+ 
per mAb 
5,9 6,2 7,5 8,2 
Recovery (%) 78 % 70 % 99 % 84 % 
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3.5. The three best antibody combinations 
The three best antibody combinations where further tested manually in immunofluorometric 
assays using F(ab’)2 fragments of the M89 solid phase antibody and Eu-labelled tracer mAbs. 
Calibrators containing 0 to 350 µg/l of recombinant HER2 (standard A-F) were used in the 
evaluation, see figure 3.3. Siemens control 1 containing recombinant HER2, two in-house 
control samples from pooled patient sera and the SK-BR-3 Breast Adenocarcinoma human 
cell line were also used in the evaluation, see table 3.4.  
 
Standard curves of the three best antibody combinations
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Figure 3.3: Standard curves for the three antibody combinations. Both axes of the figure are 
shown as logarithmic values.  
 
The antibody combinations bio-M89 and Eu-E79, and bio-M89 and Eu-M83 were superior 
compared to bio-M89 and Eu-M84. Sample concentrations determined by the standard curves 
are shown in table 3.4. Reference values defined by measuring the samples in the Siemens 
ADVIA Centaur serum HER-2/neu immunoassay were performed prior to this thesis and are 
given in the table.  
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Table 3.4: A list of the sample concentrations (µg/L) for the samples tested with the three 
antibody combinations. Reference values from the Siemens assay are also included in the 
table.  
Samples HER2 [µg/L] 
Bio-M89 and 
Eu-M79 
Bio-M89 and 
Eu-M83 
Bio-M89 and 
Eu-M84 
Siemens 
reference values 
Siemens 
Control 1 
11,271 10,414 12,262 12,75 
DNR Control 1 17,021 15,127 16,037 24,2 
DNR Control 2 98,240 83,507 148,948 204,9 
Cell line 
SK-BR3 
14,040 6,178 11,947 11,4 
 
To ensure that the best antibody combinations were chosen, the four next best antibody 
combinations from the results in figure 3.2 were also evaluated manually in 
immunofluorometric assays, with antibodies labelled with Eu3+ as reporter molecule. These 
results are only shown in Appendix 7. 
 
 
3.6. The final antibody combination 
The two different combinations bio-M89 and Eu-M79, and bio-M89 and Eu-M83 were re-
tested using the AutoDELFIA instrument (figure 3.4), to ensure that the best antibody 
combination was chosen.  
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Standard curves of the two best antibody combinations
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Figure 3.4: Standard curves of the two best antibody combinations. Both axes of the figure are 
shown as logarithmic values. 
 
The assay combination bio-M89 and Eu-M83 gave generally higher europium signals than 
bio-M89 and Eu-M79. The sample concentrations determined by the standard curves from 
figure 3.4 are shown in table 3.5. 
 
Table 3.5: The sample concentrations for the two best antibody combinations. Siemens 
reference values are also included in the table. 
 
Samples 
HER2 [µg/L] 
Bio-M89 and 
Eu-M79 
Bio-M89 and 
Eu-M83 
Siemens reference 
values 
Siemens 
Control 1 
12,43 12,08 12,75 
DNR Control 1 20,63 17,43 24,2 
DNR Control 2 101,65 85,86 204,9 
Cell line 
SK-BR3 
7,03 7,38 11,4 
 
Bio-M89 and Eu-M83 were chosen as the final antibody combination. The final immunoassay 
was further optimized. 
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3.7. Optimization of the immunoassay 
The immunoassay optimization was divided into two parts, incubation periods and reagent 
concentrations. The different incubation periods were tested and determined first, and then the 
reagent concentrations were tested and determined. Standards A-F, Siemens controls, in-
house controls and the cell line SK-BR3 were used in the optimization. Some of the control 
samples were not included in all of the optimization steps due to limited access.  
 
Two incubation periods were evaluated. The first period was the incubation after the sample 
was added to the wells, which was the second incubation period in the assay. This period was 
tested for 30, 60 and 90 minutes incubations (figure 3.5a). The other incubation period was 
the incubation after the tracer antibody was added to the wells, which was the third incubation 
period in the assay. This period was tested for 30, 60, 90 and 120 minutes incubations (figure 
3.5b).  
 
Further optimization of the immunoassay for HER2 consisted of testing the reagent 
concentrations of biotin labelled F(ab´)2 fragment of the M89 antibody and europium labelled 
tracer antibody M83. 1 µg/ml, 2 µg/ml, 3 µg/ml and 4 µg/ml concentrations were tested for 
the solid phase F(ab´)2 fragments of M89, while 0,5 µg/ml, 1 µg/ml and 2 µg/ml 
concentrations were tested for the tracer antibody M83, see figure 3.5c and 3.5d respectively.  
 
Several control samples were tested during the optimization and their concentrations were 
determined using the individual standard curves. These results, including reference values of 
the samples from the Siemens assay are presented in figure 3.6. Exact values of the sample 
concentrations are shown in table 6.6 – 6.9 in appendix 8.   
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Tracer mAb concentrations
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Figure 3.5: A presentation of the standard curves of the incubation periods and reagent 
concentrations tested during the optimization. All axes are presented as logarithmic values. 
The figures show a) the three standard curves for 30, 60 and 90 minutes incubations for the 
second incubation period, b) the standard curves for 30, 60, 90 and 120 minutes incubations 
for the third incubation period, c) the standard curves for 1 µg/ml, 2 µg/ml, 3 µg/ml and 4 
µg/ml concentrations of the biotin labelled F(ab´)2 fragment of M89, and d) the standard 
curves for 0,5 µg/ml, 1 µg/ml and 2 µg/ml Eu-M83 tracer antibody.  
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Figure 3.6: A presentation of the sample concentration results from the optimization of both 
incubation periods and reagent concentrations. The coloured bars show the different control 
samples; Red = Siemens control 1, orange = Siemens control 2, yellow = DNR control 1, 
green = DNR control 2, turquoise = SK-BR3. Siemens reference values of the samples are 
included to the right in each figure. The figures show a) control sample concentrations from 
the optimization of the second incubation period, b) control sample concentrations from the 
optimization of the third incubation period, c) control sample concentrations from the 
optimization of smAb concentrations, and d) control sample concentrations from the 
optimization of tracer mAb concentrations.   
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3.8. HER2 ECD in patient samples 
The assay was standardized towards the Siemens ADVIA Centaur serum HER-2/neu 
immunoassay, meaning that the concentrations of the calibrators (standard A-F) were 
determined by measuring them as samples in the Siemens assay. This made it possible to 
compare the results from the final HER2 assay with values from the same patient samples 
tested on the Siemens assay.  
 
15 patient samples were tested in the new HER2 assay and the commercial Siemens assay. 
The samples were from tissue HER2 positive breast cancer patients tested by 
immunohistochemistry. The results are shown in table 3.6. The table also includes the 
individual coefficients of variation (CV) of the samples in the new HER2 assay. A correlation 
curve of the 15 patient samples tested in the two assays is shown in figure 3.7. 
 
Table 3.6: 15 patient samples tested in the Siemens assay and in the new HER2 assay, 
including the CV (%) of each sample tested in the new assay.  
Siemens serum HER2 
[µg/ml] 
DNR HER2 [µg/ml] CV (%) 
12,1 4,83 0,9 
15,1 6,27 1,3 
30,7 26,46 2,4 
17,3 13,96 0,1 
2350,3 1116,41 0,4 
48,7 15,99 3,5 
10,5 3,67 2,2 
74,8 78,98 1,5 
38,4 33,32 5,1 
145,3 128,53 0,4 
18,5 14,85 5,3 
280,6 223,99 1,3 
19,7 16,09 2,2 
15,7 7,29 1,9 
649,8 395,18 1,5 
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Figure 3.7: The correlation curve of the 15 patient samples, shown as the Siemens assay vs. 
the new HER2 assay.  
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4. Discussion 
4.1. Characterization and evaluation of the antibodies for the 
development of an immunoassay for HER2 ECD 
In this master thesis, the aim was to develop an immunometric assay using monoclonal 
antibodies specific for the extracellular domain of HER2. An advantage of immunometric 
assays is the use of mAbs in excess, favouring the formation of the antigen-antibody complex. 
This enhances the sensitivity and improves the assay kinetics. However, interference from 
heterophilic antibodies can be a challenge in immunometric assays, and it is critical that the 
final assay is protected against interference [23]. 
 
The six different antibodies towards HER2 were characterized by cross-inhibition and 
isotyping. Based on the cross-inhibition results, the antibodies were divided into three 
different groups (A, B and C), where group A was further subdivided into A1 and A2 (table 
3.1). Antibody combinations that showed complete inhibition in the cross-inhibition test 
indicate a poor combination, where the antibodies most likely bind to the same epitope or 
neighbour epitopes on the HER2 antigen. The cross-inhibition tests also resulted in several 
antibody combinations with low percent inhibition, and thus make a good basis for 
constructing a sandwich assay. The isotyping of the mAbs resulted in a majority of IgG1 
isotypes, except for mAb M83 that possessed IgG2a. All of the mAbs comprised kappa light 
chains. The isotyping result may be explained by the genetic background of the BALB/c mice 
for favouring the IgG1 isotype during the immune response towards the immunogen.  
 
Combining the antibodies using recombinant HER2 as antigen was performed to find the best 
antibody combination. There were three antibody combinations that were significantly better 
than the others, and had almost twice as high binding to HER2 than the four next best 
combinations (figure 3.2). These three antibody combinations were therefore expected to have 
a low percent inhibition result from the cross-inhibition test. The three best mAb 
combinations, bio-M89 and 125I-M79, bio-M89 and 125I-M83, and bio-M89 and 125I-M84, had 
only -1 %, 3 % and 5 % inhibition in the cross-inhibition test, respectively. Thus, the low 
percent inhibition result correlated with the results from the antibody combination test. When 
testing antibody combinations with two identical mAbs, a poor combination outcome is 
expected, since the antibodies contain similar paratopes that will bind to the same epitope on 
	  	  	  	  
	   Discussion	   	  	   	  
35	  
the antigen. This corresponds to the results from the cross-inhibition testing, where every 
combination test with identical antibodies got almost 100 %. Antibodies in the other 
combinations that got almost 100 % inhibition, bind to the same epitope or to nearby epitopes. 
When the first (solid phase) antibody binds to the antigen, the antigen may undergo a 
conformational change due to the binding, which may result in non-overlapping binding sites 
for the second antibody and result in a lower percent inhibition value. This may explain the 
negative percent inhibition values.  
 
The three best mAb combinations were further tested, using Eu3+ as tracer molecule, against a 
calibration curve with recombinant HER2 and against several control samples. The standard 
curves for the mAb combinations bio-M89 and Eu-M79, and bio-M89 and Eu-M83 were 
linear with high sensitivity, while the standard curve for bio-M89 and Eu-M84 was far from 
linear and had a lower sensitivity (figure 3.3). Bio-M89 and Eu-M84 was therefore excluded 
as a suitable antibody combination. The standard curve for bio-M89 and Eu-M83 had 
generally higher Eu3+ cps-values than bio-M89 and Eu-M79, and was therefore more 
sensitive. The control samples and the breast cancer cell line gave similar values in both 
combinations (Table 3.5). Thus, the combination of bio-M89 and Eu-M83 was chosen as the 
final assay combination because it had the highest sensitivity.      
 
Europium was used as tracer molecule because of its superior sensitivity. The number of 
labelled europium molecules per antibody affects the sensitivity of the assay, where a good 
incorporation will increase the sensitivity. However, incorporation of too many europium 
molecules may change the protein structure and potentially affect the antibody’s ability to 
bind to the antigen. An incorporation of 4-15 europium molecules per antibody is considered 
to be optimal (DELFIA Eu-labelling Reagent 1244-301 protocol, Wallac, Perkin Elmer life 
sciences). The antibodies labelled with Eu3+ had between 5,9 and 8,2 europium molecules per 
antibody (table 3.3), thus there were a good and comparable europium incorporation of the 
antibodies that enhances the sensitivity of the assay. The percent recovery for the europium 
labelled antibodies was between 70 – 99 %, which was as expected. 
 
 
 
 
	  	  	  	  
	   Discussion	   	  	   	  
36	  
4.2. Optimization of the immunoassay for HER2 ECD 
It was important to do an optimization of incubation periods and reagent concentrations for 
the immunometric assay for several reasons. The incubation lengths affect the efficiency of 
the assay. The incubation periods have to be long enough for complete reactions to occur, but 
too long incubations will make the assay less efficient. The antibody and reagent 
concentrations also affect the sensitivity of the assay. It is important that the assay has a high 
sensitivity, however, using more antibodies and reagents than necessary will only increase the 
costs.   
 
The assay consisted of three incubation periods. The first incubation period was not optimized 
due to the instant binding between streptavidin and biotin (KD = 4 x 10-14 M) and 30 minutes 
is enough time for the biotin and streptavidin to bind. The second incubation period was 
tested for 30, 60 and 90 minutes incubations. The resulting standard curves were good and 
linear for the three incubation tests (figure 3.5a). The standard curve for the 30 minutes 
incubation had considerably lower Eu3+ cps-values than incubation for 60 and 90 minutes, and 
was therefore excluded as an option. Incubation for 60 and 90 minutes gave almost similar 
Eu3+ cps values, where the standard curve for 90 minutes incubation had slightly higher Eu3+ 
cps. Although 90 minutes incubation time gave slightly better sensitivity than 60 minutes, 60 
minutes incubation was chosen because the time saved was considered more valuable.  
 
The third incubation period was tested for 30, 60, 90 and 120 minutes. The four resulting 
standard curves were rather similar and the signals for the highest calibrator were quite 
similar (figure 3.5b). The sample concentrations for the 30 minutes incubation were lower 
than for the other three. The incubations for 60 and 90 minutes resulted in somewhat similar 
concentrations, while 120 minutes incubation gave the highest results. However, even though 
120 minutes incubations resulted in higher concentration values, the increase was not worth 
the longer assay duration, and thus 60 minutes was chosen as the best incubation time for the 
third incubation period. 
 
Biotin labelled M89 F(ab´)2 fragment with 1, 2, 3 and 4 µg/ml concentrations were tested 
during the optimization of reagent concentrations (figure 3.5c). Due to the low Eu3+ -counts 
for the highest calibrator when using 1 µg/ml bio-M89, and no significant increase in Eu3+ -
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counts using 3 µg/ml and 4 µg/ml concentrations, 2 µg/ml of biotin labelled M89 F(ab´)2 was 
chosen as the concentration of the solid phase antibody. 
 
Concentrations of 0,5 µg/ml, 1,0 µg/ml and 2,0 µg/ml were tested for M83 tracer antibody 
and the respective standard curves appear almost as one joint line (figure 3.5d), indicating no 
difference between the tested concentrations. The control samples and cell line SK-BR3 
concentrations were rather similar as well (figure 3.6d). 1 µg/ml europium labelled M83 is 
usually utilized [8], and 1 µg/ml tracer concentration was therefore chosen, since neither of 
the other two concentrations gave better results. 
 
 
4.3. Protection of the assay against interference 
There were several ways that the final assay was protected against interference. The M89 
antibody utilized as solid phase in the final assay was fragmented using bromelain, and F(ab)2 
- fragments were used in the final assay. Using F(ab)2 – fragments when testing patient 
samples is important, because it eliminates interference from heterophilic antibodies that are 
able to cross react with the assay by binding to the Fc – part of the antibodies. However, when 
testing antibody pair combinations and optimizing the best combination, it was not necessary 
to utilize F(ab)2 –fragments, and the whole antibody was utilized during these tests. 
Aggregated immunoglobulin was added to the buffer to block interference from potential 
heterophilic antibodies that bind to other parts of the antibody, to protect the final assay when 
testing patient samples. 
 
 
4.4. HER2 ECD in patient samples 
The final developed assay had a high sensitivity and specificity towards HER2 ECD. The 
assay was further used to test 15 patient samples from patients that were HER2 positive by 
immunohistochemistry. It is very important that the assay is reproducible and stable. The 
individual CV values for the assay after testing the patient samples were between 0,1 and 5,3 
%, indicating a good reproducibility within the assay. 
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The 15 patient samples were also tested in the Siemens assay. The values of the patient 
samples from the final HER2 assay was generally lower than for the Siemens assay (table 
3.6), however, there was a good linear correlation between the sample values from the two 
assays (figure 3.7). From the patient results, it can be expected that the new assay will give 
lower values in serum samples from normal individuals compared to the Siemens assay. Thus, 
the discrepancy between the two assays may probably be explained by a lower cut-off value 
for the new assay compared to the cut-off value of 15 ng/ml for the Siemens assay. A 
sensitive immunoassay specific for the extracellular domain of HER2 was successfully 
developed.  
 
 
4.5. Future perspectives 
Before the new HER2 assay potentially can be used for follow-up of HER2 positive patients, 
a cut-off value for the assay must be determined using an appropriate number of samples from 
healthy people. In addition, a large study with HER2 positive patient samples must be 
performed to determine the clinical usefulness of the assay. 
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6. Appendix 
6.1. Appendix 1: Chemicals and proteins 
 
Table 6.1 A list of the different chemicals utilized in the thesis, including the manufacturer 
with address, and catalogue number and degree of purity.  
Chemical Manufacturer Product/catalogue 
number 
Purity 
Borate Merck, 64271 
Darmstadt Germany 
Art. 165 99,8 % 
Bovine serum 
albumin (BSA) 
Sigma-Aldrich,  
St. Louis, USA 
A4503 ≥ 96 % 
 
Bromelain, ID-
Diluent 1 
Bio Rad 
Laboratories,  
(DiaMed-ID), 1785 
Cressier FR 
Switzerland 
  
Bromophenol blue Chroma-gesellschaft, 
Münster, Germany 
4F093  
Citric acid Riedel-de Haën AG 
seelze hannover 
33114 99,5 % 
D-sorbitol Sigma-Aldrich,  
St. Louis, USA 
S1876 ≥ 98 % 
Diethylenetriamine 
pentaacetic acid 
(DTPA) 
Sigma-Aldrich,  
St. Louis MO 6378 
U.S.A. 
D6518 ≥ 99 % 
Ethanol 96 %, 
Rektifisert sprit 
Kemetyl Norge AS, 
Delitoppen 3, N-
1540 Vestby	  
200-578-6  
Ethylene diamine 
tetra-acetate (EDTA) 
Sigma-Aldrich Co, 
P.O. Box 14508 St. 
Louis, MO 63178 St. 
Louis, USA 
E-5134 99 – 101 % 
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Ethylene glycol 
 
Sigma-Aldrich, Co. 
3050 Spruce Street, 
St. Louis, MO 63103 
USA 
03750 ≥ 99,5 % 
Europium p-
isothiocyanatophenyl-
EDTA complex 
Kaivogen OY, 
Turku, Finland 
  
EZ-link Sulfo –NHS-
LC Biotin 
Thermo scientific 21327  
Germall Allan Sjøstrand A/B   
Glycerol Merck, 64271 
Darmstadt Germany 
K31116193 236 99-100 % 
Glycine Sigma-Aldrich Co, 
P.O. Box 14508 St. 
Louis, MO 63178 
USA 
G7126 
 
≥ 99 % 
Iodine-125 Hartmann analytic 185299  
Methiolat- 
Thimerosal 
Sigma-Aldrich,  
St. Louis, USA 
T5125  
Na2HPO4 Merck, 64271 
Darmstadt Germany 
A0110846 003 99 – 102 % 
NaCl Merck, 64271 
Darmstadt Germany 
K42436404 142 99,5 % 
NaN3 Merck, 64271 
Darmstadt Germany 
106688 0250 > 99 % 
NaOH Merck, 64271 
Darmstadt Germany 
B676398 522 99 % 
Sodium dodecyl 
sulphate (SDS) 
 
Bethesda Research 
Laboratories, Life 
Technologies Inc. 
Gaithersburg, MD 
20877 U.S.A. 
5525UA 
 
99,5 % 
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Tartrazine Aldrich Chemical 
Co.Ltd. Gillingham, 
Dorset, England 
  
Tris Sigma Life 
Technologies, Inc. 
Gaithersburg, MD 
20898 USA 
T1378 99 % 
Tween 20 Serva, D-69115 
Heidelberg Carl-
Benz 
  
Tyrosine 
 
Sigma-Aldrich,  
St. Louis, USA 
T3754 ≥ 98 % 
 
 
6.2. Table with recombinant and native proteins. 
Protein Manufacturer Catalogue number Purity 
Bovine IgG Sigma-Aldrich,  
St. Louis, USA 
G7516 ≥ 97 % 
E-64 protease 
inhibitor 
Roche,  
Indianapolis, USA 
10874523001  
HER2 Sino Biological Inc, 
B-212 Zhonghe 
Street, BDA Beijing 
100176 
10004-H08H 97 %  
 
MAK 33 Roche, 
Indianapolis, USA 
11939661  
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6.2. Appendix 2: Fragmentation of antibodies to F(ab´)2 
 
Calculations for the fragmentation of the M89 antibody sample: 
 
Calculating the concentration and amount of antibody: 
Volume of sample with antibody= 11,77 ml.  
A280 nm = 2,53 
A280 nm/the extinction coefficient = 2,53/1,43 = 1,8 mg/ml 
1,8 mg/ml * 11,77 ml = 20,8 mg 
 
Calculation of the bromelain volume added:  
mg monoclonal antibody = ml bromelain 
3 * 20 
Since the bromelain concentration is 3 mg/ml, and the ratio between antibody and bromelain 
should be 1:20 in terms of weight, 20 needed to be multiplied with 3. 
20,8 mg = 0,347 ml 
3*20 
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6.3. Appendix 3: Calculation of the number of labelled Eu3+ per 
antibody and percent recovery 
 
A calculation example for antibody M79: 
Eu3+ (µmol/l) = (Eu3+ signal for M79)/ (Eu3+ signal for standard (1nmol/l) * 1000) 
Eu3+ (µmol/l) = (2118966 * 104)/ (1,06 * 106 *103) 
Eu3+ (µmol/l) = 20 
 
M79 (mg/ml) = (A280 – 0,008 * Eu3+ (µmol/l)) / extinction coefficient 
M79 (mg/ml) = (0,944 – 0,16) / 1,43 
M79 (mg/ml) = 0,548 
 
M79 (µmol/l) = (M79 (mg/ml) * 106) / 160 000 (g/l) 
M79 (µmol/l) = (0,548 * 106) / 160 000 
M79 (µmol/l) = 3,4 
 
Eu3+ per M79  = Eu3+ (µmol/l) / M79 (µmol/l) 
Eu3+ per M79  = 20 / 3,4 
Eu3+ per M79  = 5,9 
 
Recovery (%)  = M79 recovered (mg) * 100 % / M79 added (mg) 
Recovery (%)  = (1,096 * 100 %) / 1,4 
Recovery (%)  = 78 %  
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6.4. Appendix 4: Calculations during the coating of plates with 
different antibodies 
 
Table 6.3: The table gives an overview of the antibodies with their respective concentrations. 
 Antibodies 
M75 M77 M79 M83 M84 M89 
Concentration 
mg/ml 
1,44 1,06 0,92 1,25 1,56 1,8 
 
Amount and volume of the antibody per well: 1 µg/well and 200 µl/well. 
 
Total volume per plate:  
0,2 ml/well * 100 wells/plate * 1 plate = 20 ml 
There were 96 wells per plate and this number was rounded up to 100. 
 
Total amount of antibody per plate:  
1 µg/well * 100 wells/plate * 1 plate = 100 µg = 0,1 mg  
 
Calculation example for the dilution of the M75 antibody: 
 
0,1 mg  = 0,069 ml = 69 µl 
1,44 mg/ml 
69 µl M75 was diluted in 20 ml buffer. 
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6.5. Appendix 5: Cross-inhibition of HER2 mAbs 
 
50 µl of iodine labelled recombinant HER2 measured 11 047 cpm which is ∼ 10 000 cpm. 
The antibodies were diluted to 100 µg/ml in PBS with 0,3 % BSA. A total volume of 1 ml = 
1000 µl.  
 
A calculation example of this dilution: 
M75: 1,44 mg/ml = 1440 µg/ml 
1440 µg/ml = 14,4 
100 µg/ml 
1000 µl / 14,4 = 69,4 µl M75 
69,4 µl M75 was added to PBS with 0,3 % BSA to a total volume of 1 ml. 
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6.6. Appendix 6: Table of all the antibody combinations 
 
Table 6.4: The table presents the results from the antibody combination test, where the three 
best antibody combinations are marked in bold. PBS with 0,3 % BSA was used as a control, 
while HER2 100 µg/L indicates how good the antibody combination was.  
 
smAb 
 Iodine labelled monoclonal antibodies 
M75 M77 M79 M83 M84 M89 
M75 PBS with  
0,3 % BSA 
0,1 0,1 1,3 0,7 1,9 0,1 
HER2  
100 µg/L 
0,8 0,5 13,7 11,5 52,8 4,0 
M77 PBS with  
0,3 % BSA 
0,1 0,1 1,0 0,5 0,2 0,1 
HER2  
100 µg/L 
1,7 0,1 21,0 16,4 10,7 0,4 
M79 PBS with  
0,3 % BSA 
0,3 0,2 0,6 0,2 1,7 0,1 
HER2  
100 µg/L 
20,6 19,2 1,6 0,7 40,2 44,3 
M83 PBS with  
0,3 % BSA 
0,3 0,1 0,7 0,4 1,3 0,1 
HER2  
100 µg/L 
19,6 16,5 1,7 0,8 39,5 46,1 
M84 PBS with  
0,3 % BSA 
0,2 0,1 3,6 2,2 0,1 0,1 
HER2  
100 µg/L 
7,1 4,6 14,1 17,5 0,4 16,0 
M89 PBS with  
0,3 % BSA 
0,1 0,1 0,5 0,3 0,1 0,1 
HER2  
100 µg/L 
12,1 0,1 78,9 84,7 78,4 1,2 
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6.7. Appendix 7: A table with the results from the evaluation of 
the four next best antibody combinations 
 
Table 6.5: The four next best antibody combinations. The results are shown as Eu3+ [cps]. 
Standard B-M75 and Eu-
M84 
B-M79 and Eu-
M84 
B-M79 and Eu-
M89 
B-M83 and Eu-
M84 
A 3579 1830 2637 3328 
B 2685 2295 17352 1775 
C 4299 2809 71610 3184 
D 16688 11254 208754 16059 
E 106282 82146 652956 91956 
F 303501 444164 1532629 638524 
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6.8. Appendix 8: Tables with the exact values of the results 
from the optimization of the final assay 
 
Table 6.6: The table presents the sample concentration results after testing 30, 60 and 90 
minutes incubations for the second incubation period and reference values from the Siemens 
assay.  
 
Samples 
Concentration (µg/L) 
30 minutes 
incubation 
60 minutes incubation 90 minutes 
incubation 
Siemens 
reference values 
Siemens 
Control 1 
13,04 13,29 12,80 12,75 
Siemens 
Control 2 
101,78 96,61 96,32 98,2 
Cell line  
SK-BR3 
7,39 7,31 7,04 11,4 
 
 
Table 6.7: An overview of the concentrations for the control samples tested during the 
optimization of the third incubation period. Reference values from the Siemens assay are also 
given in the table. 
 
Samples 
Concentration (µg/L) 
30 minutes 
incubation 
60 minutes 
incubation 
90 minutes 
incubation 
120 minutes 
incubation 
Siemens 
reference 
values 
DNR  
Control 1 
15,21 16,11 15,56 18,00 24,2 
DNR  
Control 2 
70,40 85,07 92,59 104,37 204,9 
Siemens 
Control 1 
11,41 14,00 11,52 14,61 12,75 
Siemens 
Control 2 
73,92 86,78 86,27 88,38 98,2 
Cell line  
SK-BR3 
5,66 6,35 8,49 6,24 11,4 
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Table 6.8: The table gives an overview of the sample concentrations after testing different 
concentrations of the solid phase, and reference values from the Siemens assay.  
 
Samples 
Concentration (µg/L) 
1 µg/ml solid 
phase Ab 
2 µg/ml solid 
phase Ab 
3 µg/ml solid 
phase Ab 
4 µg/ml solid 
phase Ab 
Siemens 
reference 
values 
Siemens 
Control 1 
14,66 14,43 14,04 15,09 12,75 
DNR 
Control 1 
19,24 19,26 17,24 19,61 24,2 
DNR 
Control 2 
83,71 83,45 90,35 96,55 204,9 
Cell line 
SK-BR3 
8,32 8,86 8,48 10,24 11,4 
 
 
Table 6.9: An overview of the sample concentrations after testing 0,5 µg/ml, 1 µg/ml and 2 
µg/ml concentrations of europium labelled M83 and Siemens reference values. 
 
Samples 
Concentration (µg/L) 
0,5 µg/ml 
tracer Ab 
1 µg/ml 
tracer Ab 
2 µg/ml 
tracer Ab 
Siemens 
reference values 
Siemens 
Control 1 
13,01 12,00 
 
13,41 12,75 
Siemens 
Control 2 
93,25 85,62 85,00 98,2 
Cell line 
SK-BR3 
7,11 7,29 8,30 11,4 
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